HER2 Support Group Forums - View Single Post - Combined ER and HER-targeted therapy in breast cancer treatment

Rich66 · 06-05-2009, 09:05 PM

Yeah...seems like it would be a good argument for continued her2 blockade (Herceptin or Tykerb).
I reread this with interest:

"Using a combination of HER inhibitors to completely block the HER pathway together with ER blockade is very potent therapy in preclinical xenograft models of ER+/HER2+ tumors and is able to eradicate tumors even after short term therapy."

Me thinks Herceptin and Tykerb + Faslodex

Add Zoledronic acid to prevent bone mets and add overall benefit.

maybe add in Everolimus:
http://www.newsrx.com/library/topics...ancer/186.html

The researchers concluded: "The combination of trastuzumab and the mTOR inhibitor RAD001 also slowed breast cancer cell growth in vitro and in vivo Combining trastuzumab with inhibitors of the Akt/mTOR pathway is a clinically applicable strategy and combinations of trastuzumab with triciribine or RAD001 are promising regimens for rescue of trastuzumab resistance caused by PTEN loss."

06-05-2009, 09:05 PM	#4
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	Yeah...seems like it would be a good argument for continued her2 blockade (Herceptin or Tykerb). I reread this with interest: "Using a combination of HER inhibitors to completely block the HER pathway together with ER blockade is very potent therapy in preclinical xenograft models of ER+/HER2+ tumors and is able to eradicate tumors even after short term therapy." Me thinks Herceptin and Tykerb + Faslodex Add Zoledronic acid to prevent bone mets and add overall benefit. maybe add in Everolimus: http://www.newsrx.com/library/topics...ancer/186.html The researchers concluded: "The combination of trastuzumab and the mTOR inhibitor RAD001 also slowed breast cancer cell growth in vitro and in vivo Combining trastuzumab with inhibitors of the Akt/mTOR pathway is a clinically applicable strategy and combinations of trastuzumab with triciribine or RAD001 are promising regimens for rescue of trastuzumab resistance caused by PTEN loss."